Medpace Holdings (MEDP) Earnings Date & Reports

Key Takeaways

• Revenue reached $707.3 million, up 17.2% year-over-year and above analyst estimates.
• GAAP diluted EPS of $4.25 beat consensus expectations and rose from $3.10 in the prior-year quarter.
• Net new business awards grew 28.2% to $795.7 million, yielding a book-to-bill ratio of 1.13x.
• EBITDA margin held steady at 21.7% while net income margin improved to 17.2%.
• Full-year 2026 guidance was raised, with revenue now projected at $2.805 billion to $2.885 billion.
• Shares rose sharply in after-hours trading following the release.

Earnings Context and Why It Matters

Medpace Holdings, Inc. is a clinical contract research organization (CRO) that provides outsourced drug and medical device development services. The second quarter 2026 results offer investors an update on demand trends in the biopharmaceutical sector and the company’s ability to convert backlog into revenue. Strong awards growth and margin expansion signal operational momentum in a competitive industry where clinical trial activity directly influences long-term revenue visibility.

Reported Results

Medpace reported revenue of $707.3 million for the second quarter ended June 30, 2026, a 17.2% increase from $603.3 million a year earlier. GAAP net income totaled $121.4 million, or $4.25 per diluted share, compared with $90.3 million, or $3.10 per diluted share, in the second quarter of 2025. Net income margin expanded to 17.2% from 15.0%. EBITDA rose 17.6% to $153.4 million, representing a 21.7% margin. Net new business awards increased 28.2% to $795.7 million, producing a net book-to-bill ratio of 1.13x. Backlog stood at $3,014.2 million, up 4.9% year-over-year.

The company raised its full-year 2026 outlook. Revenue is now expected in the range of $2.805 billion to $2.885 billion, implying 10.9% to 14.0% growth over 2025 revenue of $2.530 billion. GAAP net income is forecasted between $494.0 million and $514.0 million, with diluted EPS projected at $17.25 to $17.95.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. AI Screener

Market Reaction and Investor Sentiment

Investors responded positively to the earnings beat and upwardly revised guidance. Shares traded sharply higher in after-hours activity, reflecting optimism about sustained demand for clinical development services and the company’s improving profitability. The results reinforced confidence in Medpace’s backlog conversion and new business momentum heading into the second half of the year.

Forward Outlook and Key Factors to Monitor

Management’s updated 2026 guidance incorporates stronger revenue growth assumptions and improved earnings visibility. Investors will track the pace of backlog conversion, which stood at 24.1% in the quarter, and any updates on therapeutic area concentration, particularly in oncology and cardiology.

Additional items to watch include operating margin trends amid potential pricing pressure and foreign exchange impacts. Cash flow generation and share repurchase activity remain relevant, with $527.0 million still available under the authorized program as of quarter end.

Broader industry dynamics, such as biopharmaceutical research and development spending and clinical trial outsourcing trends, will influence demand for Medpace’s services. The next quarterly update is expected in late October 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations